Vertaling van "applications increasing " (Nederlands → Frans) :

TERMINOLOGIE

extracorporele applicator voor hyperthermiesysteem voor extravasculaire circulatie
applicateur extracorporel de système d’hyperthermie de circulation extravasculaire

handbediende applicator voor brachytherapiesysteem voor oog
applicateur manuel de système de brachythérapie oculaire

applicator voor aneurysmaclip
applicateur de clips d’anévrisme

applicator voor thermisch pulsatiesysteem voor ooglid
applicateur pour système de traitement thermique par impulsions sur les paupières

applicator voor oesofageaal brachytherapiesysteem met op afstand bedienbare afterloading
applicateur de système de brachythérapie pour l’œsophage à chargement différé à distance

intracorporele applicator voor hyperthermiesysteem voor extravasculaire circulatie
applicateur intracorporel de système d’hyperthermie de circulation extravasculaire

handbediende applicator voor oesofageaal brachytherapiesysteem
applicateur manuel de système de brachythérapie pour l’œsophage

applicator voor compressiekousen
enfile-bas de contention

applicator voor dermale anesthesie
applicateur dermique d’anesthésie locale

applicator voor tandheelkundige hars
applicateur de matériau de restauration dentaire

IN-CONTEXT TRANSLATIONS

Import-Export licence The graph below shows the upward trend since 2002, with the number of applications increasing from 350 to 400 per year.
Import-Export licence The graph below shows the upward trend since 2002, with the number of applications increasing from 350 to 400 per year.

Considerable attention was focused in 2007 on increased cooperation on the part of the FAMHP with the ethics committees, with the following results: ●● An interactive website with a web application that makes possible the “simple” management of communication actions between the different ethics committees, the FAMHP, the sponsors and researchers, and also monitors the different stages in the evaluation of each application by the ethics committees ●● Systematic consultation for the more complex scientific applications ●● Further optimisation of the functioning of
Considerable attention was focused in 2007 on increased cooperation on the part of the FAMHP with the ethics committees, with the following results: ●● An interactive website with a web application that makes possible the “simple” management of communication actions between the different ethics committees, the FAMHP, the sponsors and researchers, and also monitors the different stages in the evaluation of each application by the ethics committees ●● Systematic consultation for the more complex scientific applications ●● Further optimisation of the functioning of

The figures in the table show a 10% increase for 2007 in applications finalised by the unit compared with applications received.
The figures in the table show a 10% increase for 2007 in applications finalised by the unit compared with applications received.

There was an increase in the total number of applications for evaluation, with a significant rise in particular in the number of PSUR.
There was an increase in the total number of applications for evaluation, with a significant rise in particular in the number of PSUR.

The FAMHP intends to significantly increase its involvement in the lifecycle of immunological medicines for veterinary use by providing scientific advice, evaluating applications for clinical trials in Belgium, adopting (co-)rapporteurships for CP, MRP and DCP for MA of vaccines for veterinary use and developing pharmacovigilance and inspection activities.
The FAMHP intends to significantly increase its involvement in the lifecycle of immunological medicines for veterinary use by providing scientific advice, evaluating applications for clinical trials in Belgium, adopting (co-)rapporteurships for CP, MRP and DCP for MA of vaccines for veterinary use and developing pharmacovigilance and inspection activities.

In 2008, there was a significant increase observed in the number of applications for clinical trials and amendments (changes to an existing file) and of the percentage of phase I trials. The absolute number of non-commercial (“academic”) trials remained stable.
In 2008, there was a significant increase observed in the number of applications for clinical trials and amendments (changes to an existing file) and of the percentage of phase I trials. The absolute number of non-commercial (“academic”) trials remained stable.